ON-Q* Elastomeric Infusion Pump and ambIT* Disposable Electronic Infusion Pump to Receive Separate Payment Under NOPAIN Act Starting January 1, 2025

Core Viewpoint - Avanos Medical, Inc. has received confirmation from the Centers for Medicare and Medicaid Services (CMS) regarding the inclusion of its ON-Q and ambIT infusion pumps under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, allowing for separate Medicare reimbursement starting January 1, 2025 [1][3][6]. Group 1: NOPAIN Act Implementation - The NOPAIN Act, part of the Consolidated Appropriation Act of 2023, aims to enhance patient access to non-opioid pain management solutions by providing additional Medicare reimbursement for qualifying non-opioid drugs and devices [2]. - CMS has confirmed that the ON-Q and ambIT infusion pumps meet the qualifying requirements for separate payment under the NOPAIN Act, marking a significant milestone for Avanos Medical [3][4]. - The payment limitation for both the ON-Q and ambIT infusion systems is set at up to $2,284.98, with unique HCPCS codes assigned for claim submissions starting January 1, 2025 [5]. Group 2: Impact on Pain Management - The NOPAIN Act mandates separate payment for qualified non-opioid treatments through December 31, 2027, when provided with a covered surgical procedure, aiming to reduce opioid reliance in postoperative care [6]. - The ON-Q and ambIT devices are the first and only infusion pain pumps included under this policy, which is part of a broader strategy by CMS to combat the opioid crisis [6]. - Avanos Medical's interim CEO highlighted the effectiveness of the ON-Q and ambIT pumps in reducing opioid use post-surgery, supported by clinical trials and peer-reviewed data [7].